Hongqi Tian, Ph.D
Shanghai Kechow Pharma, Inc.
6
0
2
N/A
0
4
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Brigitte C Widemann, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
James L Gulley, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Lillian Siu, MD
Princess Margaret Cancer Centre
Shared therapeutic areas:
lin shen
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Yifan Zhai, MD, PhD
Ascentage Pharma Group Inc.
Shared therapeutic areas:
You Lu, MD
West China Hospital
Shared therapeutic areas:
Barbara Murphy, MD
Vanderbilt-Ingram Cancer Center
Shared therapeutic areas:
Xiaoli Lan, PhD
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Shared therapeutic areas:
Peng Wang, MD
Fudan University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
All 6 trials loaded